Drug intelligence / Profile preview

Glucozan

Development stage: Preclinical
Lead developer: TradoMed
Administration: Oral

Overview

Glucozan is a botanical phytomedicine developed by TradoMed (Trado-Medical Services) for the management of Type 2 diabetes. Positioned as an herbal antidiabetic remedy, it is part of a pipeline aimed at standardizing traditional African medicinal knowledge into clinically validated therapies. The product is formulated to assist in blood glucose regulation, although its specific constituent plant extracts and molecular mechanisms of action are not publicly detailed. It represents an effort to bridge traditional medicine with modern clinical standards for metabolic disorders.

Brand names: Glucozan
Other names: Glucozan

Beyond the preview

Go deeper on Glucozan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glucozan.

Explore the full profile